Revium Rx. (RVRC)
| Market Cap | 101.42M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -13.45M |
| Shares Out | 60.73M |
| EPS (ttm) | -0.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 101 |
| Average Volume | 262 |
| Open | 1.670 |
| Previous Close | 1.670 |
| Day's Range | 1.670 - 1.670 |
| 52-Week Range | 0.520 - 1.670 |
| Beta | -0.61 |
| RSI | 48.63 |
| Earnings Date | n/a |
About Revium Rx.
Revium Rx. operates as a pre-clinical stage biopharmaceutical company focused on the development of nanoparticle-based therapies in the United States. The company develops lipid-based platforms for a variety of uses including antimicrobial resistance and solid tumors. The company specializes in infectious diseases, including antibiotic-resistant infections, solid tumors and vaccination. The company also develops nano-liposomal particles (NLP) based pharmaceutical candidates. It develops nanoparticles-based formulation of a potent antibiotic; no... [Read more]
Financial Performance
Financial StatementsNews
Revium Rx Advances Toward Phase 1 Clinical Development of Nano-Mupirocin to Combat Antibiotic-Resistant Infections
TEL AVIV, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Revium Rx (formerly Revium Recovery Inc. (OTC: RVRC), a biopharmaceutical company developing advanced lipid-based therapeutics for infectious and on...
Correction: REVIUM RECOVERY ACQUIRES ANTI-ADDICTION REHABILITATION BUSINESS
OC Beverages changes name to “Revium Recovery, Inc.”, acquires new symbol and implements reverse stock split